MXCT - Ticker AI Digest

MaxCyte Inc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (MXCT) 1
MXCT 13:17
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
MXCT 06:01
MaxCyte Inc
First Quarter 2025 Financial Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
MaxCyte Inc. has released its financial results for the first quarter of 2025, with a focus on its core business revenue, strategic platform licensing, and overall financial performance. The company reported a 1% increase in core business revenue compared to the same quarter last year, totaling $8.2 million. However, the total revenue decreased by 8% to $10.4 million due to a decline in strategic platform license (SPL) program-related revenue. MaxCyte added a new SPL client, TG Therapeutics, bringing the total active SPLs to 29.
The companys cash, cash equivalents, and investments amounted to $174.7 million as of March 31, 2025. MaxCyte reiterated its 2025 guidance, expecting core revenue growth of 8% to 15% and SPL program-related revenue of approximately $5 million. The company expects to end the year with approximately $160 million in cash, cash equivalents, and investments.
MaxCytes first-quarter 2025 net loss was $10.3 million, with an EBITDA loss of $11.2 million. The companys operating expenses decreased to $21.2 million compared to $22.2 million in the first quarter of 2024. The companys gross profit and gross margin decreased slightly compared to the previous year, with a gross margin of 86% in the first quarter of 2025.
MaxCyte is a leading cell-engineering company, providing technologies for the development of next-generation cell therapeutics. The companys Flow Electroporation® technology and SeQure Dx™ gene editing risk assessment services enable efficient and scalable cell engineering.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 8
MXCT 13:17
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 15:18
MaxCyte Inc
Holding(s) in Company
MXCT 06:07
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 15:53
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 15:27
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 06:01
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 17:06
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 14:13
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 11
MXCT 13:17
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 16:15
MaxCyte Inc
Total Voting Rights
MXCT 15:18
MaxCyte Inc
Holding(s) in Company
MXCT 06:07
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 15:53
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 15:27
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 06:01
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 17:06
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 14:13
MaxCyte Inc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
MXCT 06:01
MaxCyte Inc
Filing of Form 10-Q
MXCT 06:01
MaxCyte Inc
First Quarter 2025 Financial Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
MaxCyte Inc. has released its financial results for the first quarter of 2025, with a focus on its core business revenue, strategic platform licensing, and overall financial performance. The company reported a 1% increase in core business revenue compared to the same quarter last year, totaling $8.2 million. However, the total revenue decreased by 8% to $10.4 million due to a decline in strategic platform license (SPL) program-related revenue. MaxCyte added a new SPL client, TG Therapeutics, bringing the total active SPLs to 29.
The companys cash, cash equivalents, and investments amounted to $174.7 million as of March 31, 2025. MaxCyte reiterated its 2025 guidance, expecting core revenue growth of 8% to 15% and SPL program-related revenue of approximately $5 million. The company expects to end the year with approximately $160 million in cash, cash equivalents, and investments.
MaxCytes first-quarter 2025 net loss was $10.3 million, with an EBITDA loss of $11.2 million. The companys operating expenses decreased to $21.2 million compared to $22.2 million in the first quarter of 2024. The companys gross profit and gross margin decreased slightly compared to the previous year, with a gross margin of 86% in the first quarter of 2025.
MaxCyte is a leading cell-engineering company, providing technologies for the development of next-generation cell therapeutics. The companys Flow Electroporation® technology and SeQure Dx™ gene editing risk assessment services enable efficient and scalable cell engineering.

AI Crunch

Single-Ticker AI Crunch
MXCT signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for MaxCyte Inc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full MXCT AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for MXCT on 2025-06-05.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
161752320
Enterprise Value
382641891
Public Float
89.48
Broker Target
538.0263
Shares Out
106319000
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
US57777K1060
Market
LSE - AIM
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
-
Net Debt
-9850000.0
Cash
27884000.0
EPS
-0.3
Net Income
-41055000.0
Revenue
38627000.0
Enterprise Value
382641891
Trailing PE
-
Forward PE
-
Price Sales TTM
4.2934
Price Book MRQ
1.1554
EV Revenue
2.9449
EV EBITDA
-9.2094

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
8.51
Institutions As Of
2025-06-12
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
1
Sale Director Dealing
10
Purchase TR1
7
Sale TR1
16
Broker Coverage Rows
0
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit MXCT.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-06-05 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
MaxCyte Inc has fresh news flow feeding the chart narrative.
AI Charts Studio
MXCT Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-06-05 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast